Related Experiment Video
Updated: May 5, 2026
The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
Screening for pre-eclampsia using pregnancy-associated plasma protein-A or placental growth factor measurements in
Insights
Pregnancy-associated plasma protein-A (PAPP-A) has limited value for early preterm pre-eclampsia screening. Placental growth factor (PlGF) significantly improves detection rates when measured at 10-14 weeks gestation.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Biomarker Research
Background:
- Preterm pre-eclampsia (PE) is a significant complication of pregnancy.
- First-trimester screening aims to identify pregnancies at high risk for PE.
- Pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) are investigated biomarkers.
Purpose of the Study:
- To evaluate the utility of PAPP-A in first-trimester screening for preterm PE.
- To compare the screening performance of PAPP-A against PlGF.
- To assess the combined predictive value of these biomarkers with maternal factors and other clinical parameters.
Main Methods:
- Analysis of data from the prospective, multicenter PRESIDE study.
- Measurement of PAPP-A and PlGF from maternal blood samples collected at 8-14 weeks gestation.
- Assessment of screening performance using detection rates at a 10% screen-positive rate (SPR) for various biomarker combinations.
Main Results:
- PAPP-A showed limited value in improving preterm PE detection rates, especially before 10 weeks gestation.
- PlGF, when measured at or after 10 weeks, significantly increased the detection rate of preterm PE.
- Combining PlGF with maternal factors alone or with maternal factors, MAP, and UtA-PI demonstrated substantial improvements in screening performance.
Conclusions:
- PAPP-A has minimal value for first-trimester screening of preterm PE.
- PlGF is a valuable biomarker for enhancing the detection of preterm PE between 10-14 weeks gestation.
- PlGF significantly improves screening performance when incorporated into first-trimester risk assessment algorithms.
Objectives:
To assess the value of pregnancy-associated plasma protein-A (PAPP-A) in screening for preterm pre-eclampsia (PE) (delivery < 37 weeks' gestation) measured in maternal blood samples collected before 11 weeks, and to compare the screening performance of PAPP-A with that of placental growth factor (PlGF) from blood samples collected at 8-14 weeks.
Methods:
This study analyzed data from women who participated in the PRESIDE (Pre-eclampsia Screening in Denmark) study, a prospective, non-interventional multicenter study investigating the predictive performance of the Fetal Medicine Foundation first-trimester screening algorithm for PE in a Danish population. As part of combined first-trimester screening, a routine blood sample was collected at 8-14 weeks' gestation and PAPP-A was measured. Excess serum was stored at -80°C and analyzed for PlGF in batches after delivery. Most women in the PRESIDE study had an extra blood sample collected at the time of the first-trimester scan at 11-14 weeks, which was also analyzed for PlGF and PAPP-A in batches after all the participants had delivered. Screening performance was assessed in terms of the detection rate at a 10% screen-positive rate (SPR) for a combination of PAPP-A or PlGF with maternal factors alone and for a combination of each of these biomarkers with maternal factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI).
Results:
The study population comprised 8386 women who had a routine combined first-trimester aneuploidy screening blood sample collected at 8-14 weeks' gestation. In pregnancies that developed preterm PE, the median PAPP-A multiples of the median from routine blood samples were 0.78 (95% CI, 0.67-0.90) before 10 weeks, 0.80 (95% CI, 0.58-1.10) at 10 weeks and 0.64 (95% CI, 0.53-0.78) at 11-14 weeks. In women with samples collected before 10 weeks, there was no significant improvement in the detection rate of preterm PE when PAPP-A or PlGF was combined with maternal factors alone or when combined with maternal factors, MAP and UtA-PI. In routine samples collected at or after 10 weeks, PAPP-A only increased the detection rate of preterm PE slightly. However, PlGF in samples collected at or after 10 weeks increased the detection rate from 31.3% (95% CI, 16.1-50.0%) to 56.3% (95% CI, 37.7-73.6%) at a 10% SPR, i.e. an increase in the detection rate of 25.0% (95% CI, 4.3-44.4%), when combined with maternal factors alone. When PlGF collected from the PRESIDE sample at 11-14 weeks was combined with maternal factors, MAP and UtA-PI, there was an increase in the detection rate from 50.9% (95% CI, 37.1-64.6%) to 67.3% (95% CI, 53.3-79.3%), i.e. an increase of 16.4% (95% CI, 5.6-29.0%) at a 10% SPR.
Conclusions:
PAPP-A has limited value in first-trimester screening for PE, whereas PlGF adds significantly to the detection rate of preterm PE at 10-14 weeks' gestation. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
